| 60S ribosomal protein L17, putative [Q4Q5P2] | |
|---|---|
| Systematic Name | LmjF.32.0430 [Leishmania major] |
| Gene Name | LMJF_32_0430 |
| Molecular Weight | 19113 Da |
| Protein Sequence Size | 166 |
| Function | |
| Charge | 29.5 |
| Isoelectric Point | 11.3196 pH |
| Description | 60S ribosomal protein L17, putative. |
| Subcellular Location | cytosolic large ribosomal subunit (sensu Eukaryota); intracellular; large ribosomal subunit; ribosome[Predict] |
| E. C. Number | N.A. |
| Sequence | >tr|Q4Q5P2|Q4Q5P2_LEIMA 60S ribosomal protein L17, putative - Leishmania major THYSRKPQVSSKSAKAKVSDLRCHYKNTFETANVINGMPLRKAQQLYRQVLAKTRCIPFK RYNGKIGRTAQAKEWGQTKGRWPRKSVVAMMSLLKNAEANAIEKGLDPNQMVIKHVQVDQ AARMRRRTYRAHGRITPYMCSPCHVQLFMSEKKERVPAPKSTPKK |
| DNA Sequence | >LmjF32.0430 |||60S ribosomal protein L17, putative|Leishmania major|chr 32|||Manual ATGACACACT ATTCCCGAAA GCCGCAGGTG TCGTCGAAGA GCGCCAAGGC GAAGGTTAGCGACCTCCGCT GCCACTACAA GAACACCTTC GAGACGGCGA ATGTGATCAA CGGCATGCCGCTTCGCAAGG CTCAGCAGCT GTACCGCCAG GTGCTCGCCA AGACCCGCTG CATCCCGTTCAAGCGCTACA ATGGCAAGAT CGGCCGCACC GCTCAGGCGA AGGAATGGGG CCAGACCAAGGGCCGCTGGC CGCGCAAGTC CGTCGTGGCG ATGATGTCGC TGCTCAAGAA CGCCGAGGCCAACGCCATCG AGAAGGGTCT CGACCCCAAC CAGATGGTCA TCAAGCACGT GCAGGTGGACCAGGCTGCCC GCATGCGCCG CCGCACGTAC CGTGCCCACG GTCGCATCAC GCCGTACATGTGCAGCCCCT GCCACGTGCA GCTGTTCATG TCGGAGAAGA AGGAGCGCGT CCCGGCCCCGAAGAGCACCC CCAAGAAGTA A |
| 60S ribosomal protein L17, putative Q4Q5P2] | |
|---|---|
| Metabolite Information | protein biosynthesis |
| Molecular Function | |
| Biochemical Pathway | |
| Regulatory Pathway | |
| KEGG Pathways | K02880 |
| Orthologs | ||||
| Homologs | GI | Percent Identity | Evalue | Score |
| Homo sapiens | ribosomal protein L17 [Homo sapiens] | 51 | 1e-47 | 186 |
| DEG Information | ||||
| DEG Protein | DEG Organism | Percent Identity | Evalue | Bit Score |
| thrC threonine synthase | Haemophilus influenzae | 26% | 2.2 | 25.8 |
| Post Translational Modification | ||||
| PTM Type | PTM Sub Type | Score | Modification Site | Prosite ID |
| PDOC00387 | Ribosomal protein L22 signature | 126-150; | PS00464 | |
| Acylation | N-myristoylation site | 77-82; 106-111; | PS00008 | |
| Phosphorylation | cAMP- and cGMP-dependent protein kinase phosphorylation site | 126-129; | PS00004 | |
| Phosphorylation | Protein kinase C phosphorylation site | 5-7; 11-13; 14-16; 129-131; 151-153; 163-165; | PS00005 | |
| 60S ribosomal protein L17, putative [Q4Q5P2] | ||
|---|---|---|
| Model Information | ||
| Template PDB ID | 1s1iN | |
| Percent Identity | 55% | |
| Target Region | 1-152 | |
| Template Region | 5-147 | |
| Domain Information | ||
|---|---|---|
| Domains | Start | End |
| Active Site Information | ||
|---|---|---|
| Residue | Active Site Number | Functional Part |
| Co-Factor | |
|---|---|
| Metal | Description |
| Ligands | |||||
|---|---|---|---|---|---|
| CAS number | Name | Mol. Weight | Mol. Formula | Smile Notation | PDB Reference |
| Mutational Information | ||
|---|---|---|
| Residue | Feature | Description |
|
|
|
| Modeled Protein | Template Structure |
|
|
+----------<<< P R O C H E C K S U M = M A R Y >>>----------+ | = | | /var/www/html/Services/SAVES_3/jobs/1587040/Q4Q5P2.pdb 2.0 152 = residues | | = | *| Ramachandran plot: 64.7% core 20.6% allow 8.1% gener 6.6% = disall | | = | *| All Ramachandrans: 31 labelled residues (out of 150) = | *| Chi1-chi2 plots: 6 labelled residues (out of 93) = | | = | +| Main-chain params: 4 better 0 inside 2 worse = | | Side-chain params: 5 better 0 inside 0 worse = | | = | *| Residue properties: Max.deviation: 18.8 Bad contacts: = 26 | *| Bond len/angle: 9.1 Morris et al class: 3 = 1 3 | +| 2 cis-peptides = | +| G-factors Dihedrals: -0.59 Covalent: -0.91 Overall: = -0.68 | | = | | M/c bond lengths: 95.1% within limits 4.9% highlighted = | *| M/c bond angles: 82.0% within limits 18.0% highlighted 4 off = graph | | Planar groups: 100.0% within limits 0.0% highlighted = | | = | = +------------------------------------------------------------------------= ----+ + May be worth investigating further. * Worth investigating further. |